Free Trial
→ Gold Alert: The Truth About Fort Knox Is Coming (From Golden Portfolio) (Ad) Buy BEAM Stock  Free BEAM Stock Alerts

Beam Therapeutics (BEAM) Financials

Beam Therapeutics logo
$19.93 +0.22 (+1.12%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Beam Therapeutics

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -91 -196 -371 -289 -133 -377
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377
Total Pre-Tax Income 		-78 -195 -371 -260 -131 -377
Total Operating Income		 -75 -133 -392 -338 -176 -416
Total Gross Profit		 0.02 0.02 52 61 378 64
Total Revenue		 0.02 0.02 52 61 378 64
Operating Revenue		 0.02 0.02 52 61 378 64
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 75 133 444 399 554 479
Selling, General & Admin Expense		 21 30 57 88 117 112
Research & Development Expense		 55 103 387 312 437 368
Total Other Income / (Expense), net		 -3.17 -62 22 78 45 39
Interest Expense		 -2.23 -1.05 0.01 -15 -47 -49
Other Income / (Expense), net		 -5.40 -63 22 63 -1.35 -10
Income Tax Expense		 - 0.00 0.00 3.41 1.37 0.04
Other Gains / (Losses), net		 - 0.00 0.00 -26 0.00 0.00
Basic Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58)
Weighted Average Basic Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M
Diluted Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58)
Weighted Average Diluted Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M
Weighted Average Basic & Diluted Shares Outstanding		 6.48M 46.73M 68.73M 72.40M 81.66M 83.69M

Quarterly Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -110 -38 -96 -83 -96 143 -99 -91 -97 -90
Consolidated Net Income / (Loss)		 -110 -38 -96 -83 -96 143 -99 -91 -97 -90
Net Income / (Loss) Continuing Operations		 -110 -38 -96 -83 -96 143 -99 -91 -97 -90
Total Pre-Tax Income 		-82 -37 0.00 -83 -96 48 0.00 -91 -97 -189
Total Operating Income		 -91 -89 -99 -102 -108 133 -104 -105 -107 -100
Total Gross Profit		 16 20 24 20 17 316 7.41 12 14 30
Total Revenue		 16 20 24 20 17 316 7.41 12 14 30
Operating Revenue		 16 20 24 20 17 316 7.41 12 14 30
Total Operating Expenses		 107 109 123 122 125 183 112 117 121 130
Selling, General & Admin Expense		 22 23 23 25 25 43 27 30 27 29
Research & Development Expense		 85 86 100 98 100 140 85 87 94 101
Total Other Income / (Expense), net		 9.64 52 2.47 19 12 11 5.46 14 9.84 9.68
Interest Expense		 -4.98 -7.61 -9.96 -12 -13 -12 -12 -14 -12 -11
Other Income / (Expense), net		 4.66 44 -7.49 7.42 -0.52 -0.76 -6.39 -0.31 -2.29 -1.25
Basic Earnings per Share		 ($1.56) ($0.54) ($1.33) ($1.08) ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09)
Weighted Average Basic Shares Outstanding		 70.34M 70.02M 72.27M 76.34M 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M
Diluted Earnings per Share		 ($1.56) ($0.54) ($1.33) ($1.08) ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09)
Weighted Average Diluted Shares Outstanding		 70.34M 70.02M 72.27M 76.34M 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M
Weighted Average Basic & Diluted Shares Outstanding		 70.47M 72.40M 76.22M 79.20M 81.50M 81.66M 82.31M 82.42M 82.81M 83.69M

Annual Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -97 126 396 -327 199 -155
Net Cash From Operating Activities		 -72 -96 -66 23 -149 -347
Net Cash From Continuing Operating Activities		 -72 -96 -66 23 -149 -347
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377
Depreciation Expense		 3.50 4.74 7.45 14 20 22
Amortization Expense		 -0.92 0.12 -0.08 -0.98 -20 -13
Non-Cash Adjustments To Reconcile Net Income		 12 92 -109 378 99 120
Changes in Operating Assets and Liabilities, net		 -8.17 2.20 406 -80 -116 -99
Net Cash From Investing Activities		 -67 -100 -294 -461 72 185
Net Cash From Continuing Investing Activities		 -66 -99 -294 -461 72 185
Purchase of Property, Plant & Equipment		 -13 -16 -47 -49 -34 -8.95
Purchase of Investments		 -130 -282 -777 -1,617 -984 -486
Divestitures		 0.00 0.00 0.62 0.00 0.00 0.00
Sale and/or Maturity of Investments		 76 199 529 1,205 1,090 680
Net Cash From Financing Activities		 41 322 756 112 276 7.74
Net Cash From Continuing Financing Activities		 41 322 756 112 276 7.74
Repayment of Debt		 -0.46 -1.57 - -2.29 -2.25 -0.49
Repurchase of Common Equity		 -2.52 -2.06 -8.82 -0.19 -0.63 0.00
Issuance of Common Equity		 0.00 320 757 111 273 2.62
Other Financing Activities, net		 0.19 3.16 7.51 2.73 6.13 5.60
Cash Interest Paid		 0.19 0.56 0.57 0.38 0.16 0.03

Quarterly Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -109 76 14 -19 -63 267 -150 4.62 -62 53
Net Cash From Operating Activities		 -74 -69 -110 -85 -90 135 -100 -83 -88 -76
Net Cash From Continuing Operating Activities		 -74 -69 -110 -85 -90 135 -100 -83 -88 -76
Net Income / (Loss) Continuing Operations		 -110 -38 -96 -83 -96 143 -99 -91 -97 -90
Consolidated Net Income / (Loss)		 -110 -38 -96 -83 -96 143 -99 -91 -97 -90
Depreciation Expense		 3.47 3.94 4.65 4.82 5.19 5.36 5.43 5.58 5.48 5.44
Amortization Expense		 -3.22 3.33 -6.93 -7.57 -7.88 2.17 -6.58 -5.93 -5.62 5.03
Non-Cash Adjustments To Reconcile Net Income		 32 4.11 31 26 35 7.81 35 33 31 21
Changes in Operating Assets and Liabilities, net		 2.85 -42 -42 -25 -26 -23 -35 -25 -22 -17
Net Cash From Investing Activities		 -36 113 25 -41 -10 98 -53 87 25 126
Net Cash From Continuing Investing Activities		 -36 113 25 -41 -10 98 -53 87 25 126
Purchase of Property, Plant & Equipment		 -12 -8.26 -6.02 -16 -7.95 -3.59 -2.44 -1.96 -1.58 -2.97
Sale and/or Maturity of Investments		 334 360 298 366 271 155 144 224 183 129
Net Cash From Financing Activities		 1.56 32 98 108 37 34 2.90 0.13 1.26 3.44
Net Cash From Continuing Financing Activities		 1.56 32 98 108 37 34 2.90 0.13 1.26 3.44
Issuance of Common Equity		 1.66 32 96 108 36 34 1.40 - 1.22 -0.00
Other Financing Activities, net		 0.50 0.76 3.39 0.70 1.29 0.75 1.68 0.24 0.24 3.45

Annual Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 156 452 1,474 1,342 1,460 1,104
Total Current Assets		 95 308 1,273 1,093 1,211 878
Cash & Equivalents		 37 162 560 233 436 282
Short-Term Investments		 55 138 406 845 754 569
Prepaid Expenses		 2.70 8.65 7.36 15 21 27
Plant, Property, & Equipment, net		 24 39 84 116 125 111
Total Noncurrent Assets		 37 105 117 133 124 114
Other Noncurrent Operating Assets		 37 105 117 133 124 114
Total Liabilities & Shareholders' Equity		 156 452 1,474 1,342 1,460 1,104
Total Liabilities		 55 206 648 608 478 370
Total Current Liabilities		 29 102 213 224 206 182
Accounts Payable		 7.85 6.31 7.47 9.03 1.62 3.87
Accrued Expenses		 7.85 18 68 50 112 47
Current Deferred Revenue		 - 0.02 86 136 69 109
Other Current Liabilities		 13 78 52 29 24 22
Total Noncurrent Liabilities		 26 104 434 385 273 188
Noncurrent Deferred Revenue		 - 0.39 262 202 110 33
Other Noncurrent Operating Liabilities		 22 103 172 182 163 155
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -201 246 827 733 981 734
Total Preferred & Common Equity		 -201 246 827 733 981 734
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -201 246 827 733 981 734
Common Stock		 1.92 643 1,595 1,793 2,171 2,299
Retained Earnings		 -203 -398 -768 -1,057 -1,190 -1,567
Accumulated Other Comprehensive Income / (Loss)		 0.02 -0.01 -0.05 -2.43 0.60 0.68

Quarterly Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 1,350 1,332 1,354 1,291 1,360 1,261 1,171
Total Current Assets		 1,109 1,083 1,095 1,040 1,122 1,029 946
Cash & Equivalents		 157 250 226 169 288 293 230
Short-Term Investments		 938 810 847 846 807 715 696
Prepaid Expenses		 14 24 22 24 27 21 20
Plant, Property, & Equipment, net		 111 122 128 128 121 117 114
Total Noncurrent Assets		 130 127 131 123 117 114 112
Other Noncurrent Operating Assets		 130 127 131 123 117 114 112
Total Liabilities & Shareholders' Equity		 1,350 1,332 1,354 1,291 1,360 1,261 1,171
Total Liabilities		 636 571 542 512 446 407 380
Total Current Liabilities		 239 220 210 220 187 177 166
Accounts Payable		 7.02 14 6.89 3.18 2.79 4.43 3.81
Accrued Expenses		 39 38 38 42 86 67 52
Current Deferred Revenue		 160 143 139 153 72 85 89
Other Current Liabilities		 33 25 26 22 26 21 21
Total Noncurrent Liabilities		 397 351 333 291 259 230 214
Noncurrent Deferred Revenue		 198 172 156 125 100 75 58
Other Noncurrent Operating Liabilities		 199 179 177 167 160 154 156
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 714 762 812 779 913 854 791
Total Preferred & Common Equity		 714 762 812 779 913 854 791
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 714 762 812 779 913 854 791
Common Stock		 1,738 1,916 2,050 2,114 2,203 2,235 2,266
Retained Earnings		 -1,019 -1,154 -1,237 -1,333 -1,289 -1,380 -1,476
Accumulated Other Comprehensive Income / (Loss)		 -4.67 -0.77 -2.02 -2.02 -0.92 -1.11 1.76

Annual Metrics and Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 33.33% 215,916.67% 17.51% 520.01% -83.18%
EBITDA Growth		 0.00% -144.69% -90.39% 27.79% 32.12% -134.19%
EBIT Growth		 0.00% -142.87% -89.44% 25.67% 35.44% -139.43%
NOPAT Growth		 0.00% -76.65% -195.62% 13.76% 47.86% -135.47%
Net Income Growth		 0.00% -148.44% -90.47% 22.00% 54.16% -184.28%
EPS Growth		 0.00% 70.18% -37.71% 28.42% 58.35% -166.28%
Operating Cash Flow Growth		 0.00% -32.97% 30.78% 133.99% -762.29% -132.75%
Free Cash Flow Firm Growth		 0.00% 0.00% -650.28% 83.58% -732.64% -47.22%
Invested Capital Growth		 0.00% -500.58% -156.72% -148.12% 39.49% 43.80%
Revenue Q/Q Growth		 0.00% 0.00% 6,538.16% -33.75% 363.14% -81.83%
EBITDA Q/Q Growth		 0.00% -53.80% 8.09% 8.54% 51.06% -112.68%
EBIT Q/Q Growth		 0.00% -52.47% 7.66% 6.71% 49.89% -121.29%
NOPAT Q/Q Growth		 0.00% -12.19% -6.13% -8.15% 55.69% -127.49%
Net Income Q/Q Growth		 0.00% -53.25% 7.66% 8.36% 57.75% -162.37%
EPS Q/Q Growth		 0.00% 39.36% 14.90% 5.28% 58.75% -189.87%
Operating Cash Flow Q/Q Growth		 0.00% -7.28% 28.28% -75.92% 57.79% -155.69%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -21.08% -154.84% 38.53% -66.23%
Invested Capital Q/Q Growth		 0.00% -2,417.92% -33.40% 9.32% 11.83% 12.83%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -433,172.22% -794,958.33% -700.67% -430.58% -47.14% -656.46%
Operating Margin		 -417,522.22% -553,166.67% -757.01% -555.61% -46.73% -654.25%
EBIT Margin		 -447,522.22% -815,179.17% -714.89% -452.19% -47.08% -670.36%
Profit (Net Income) Margin		 -435,144.44% -810,800.00% -714.91% -474.54% -35.09% -593.13%
Tax Burden Percent		 100.00% 100.00% 100.00% 111.11% 101.04% 100.01%
Interest Burden Percent		 97.23% 99.46% 100.00% 94.45% 73.75% 88.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -389.46% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -360.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 311.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.59% -112.32% -69.13% -37.06% -15.46% -43.94%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.60% -64.38% -38.48% -19.56% -12.70% -33.22%
Return on Assets (ROA)		 -50.18% -64.03% -38.49% -20.53% -9.46% -29.39%
Return on Common Equity (ROCE)		 154.58% -14.41% -69.13% -37.06% -15.46% -43.94%
Return on Equity Simple (ROE_SIMPLE)		 38.95% -79.24% -44.83% -39.41% -13.50% -51.36%
Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291
NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98%
Net Nonoperating Expense Percent (NNEP)		 -29.41% -52.52% -15.16% -5.10% -0.79% -8.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -32.30% -12.59% -39.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 114,183.33% 123,354.17% 110.37% 144.13% 30.93% 175.58%
R&D to Revenue		 303,438.89% 429,912.50% 746.64% 511.48% 115.80% 578.67%
Operating Expenses to Revenue		 417,622.22% 553,266.67% 857.01% 655.61% 146.73% 754.25%
Earnings before Interest and Taxes (EBIT)		 -81 -196 -371 -275 -178 -426
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -191 -363 -262 -178 -417
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 19.27 6.57 3.76 2.26 2.80
Price to Tangible Book Value (P/TBV)		 0.00 19.27 6.57 3.76 2.26 2.80
Price to Revenue (P/Rev)		 10,000.00 197,180.98 104.73 45.24 5.87 32.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 29.21 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 21,922.89 184,694.69 86.11 27.54 2.72 18.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 74.48 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.87 -1.12 -1.18 -1.31 -1.32 -1.19
Leverage Ratio		 1.55 1.75 1.80 1.81 1.63 1.49
Compound Leverage Factor		 1.50 1.74 1.80 1.70 1.20 1.32
Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 286.69% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -190.88% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.12 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.66 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.06 11.66 4.37 1.76 2.32 0.88
Noncontrolling Interest Sharing Ratio		 299.22% 87.17% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.24 3.01 5.96 4.89 5.89 4.82
Quick Ratio		 3.15 2.93 4.52 4.82 5.79 4.67
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -190 -31 -260 -382
Operating Cash Flow to CapEx		 -575.20% -585.32% -141.57% 46.02% -442.30% -3,881.58%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -21,102.94 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -7,363.11 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -12,564.33 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.05 0.04 0.27 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.84 0.61 3.14 0.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 14 -54 -139 -345 -209 -117
Invested Capital Turnover		 0.00 0.00 -0.54 -0.25 -1.37 -0.39
Increase / (Decrease) in Invested Capital		 0.00 -68 -85 -206 136 91
Enterprise Value (EV)		 395 4,433 4,464 1,678 1,029 1,203
Market Capitalization		 180 4,732 5,430 2,756 2,219 2,054
Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86
Tangible Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86
Total Capital		 105 246 827 733 981 734
Total Debt		 4.41 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 4.41 0.00 0.00 0.00 0.00 0.00
Net Debt		 -87 -300 -966 -1,078 -1,190 -851
Capital Expenditures (CapEx)		 13 16 47 49 34 8.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -94 94 -209 -184 -155
Debt-free Net Working Capital (DFNWC)		 65 206 1,060 869 1,005 696
Net Working Capital (NWC)		 65 206 1,060 869 1,005 696
Net Nonoperating Expense (NNE)		 26 102 96 52 8.99 86
Net Nonoperating Obligations (NNO)		 -87 -300 -966 -1,078 -1,190 -851
Total Depreciation and Amortization (D&A)		 2.58 4.85 7.38 13 -0.21 8.83
Debt-free, Cash-free Net Working Capital to Revenue		 -146,900.00% -390,362.50% 181.17% -342.80% -48.82% -243.49%
Debt-free Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88%
Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M
Adjusted Diluted Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.19) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 46.73M 68.73M 72.40M 81.66M 83.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291
Normalized NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98%
Pre Tax Income Margin		 -435,144.44% -810,800.00% -714.91% -427.08% -34.73% -593.07%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 -41,181.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -30,525.06 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -46,382.22 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -35,726.28 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.22% -1.06% -2.38% -0.07% -0.48% 0.00%

Quarterly Metrics and Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 1,970.64% -60.76% 187.10% 20.80% 8.82% 1,478.04% -69.39% -41.48% -17.01% -90.49%
EBITDA Growth		 -227.21% 39.38% -62.40% -36.74% -29.04% 470.48% -2.72% -8.27% 2.28% -165.04%
EBIT Growth		 -208.06% 30.58% -52.34% -27.99% -25.55% 393.81% -3.85% -11.06% -0.01% -176.67%
NOPAT Growth		 -31.12% -40.17% -29.78% -24.62% -18.58% 313.29% -5.26% -2.69% 1.63% -152.71%
Net Income Growth		 -289.70% 40.73% -39.36% -15.05% 12.31% 472.36% -2.29% -10.00% -0.60% -163.27%
EPS Growth		 -271.43% 29.87% -31.68% -5.88% 21.79% 453.70% 9.02% -2.78% 4.10% -157.07%
Operating Cash Flow Growth		 -2,577.42% -3,880.93% -150.26% -61.97% -20.52% 295.22% 9.17% 1.96% 1.85% -156.54%
Free Cash Flow Firm Growth		 298.29% 255.45% -163.61% -182.89% -203.45% -102.27% -15.15% -2.64% 19.48% -4,857.85%
Invested Capital Growth		 -265.01% -148.12% 24.28% 28.58% 37.77% 39.49% 39.23% 41.05% 43.16% 43.80%
Revenue Q/Q Growth		 -5.12% 26.82% 20.82% -16.90% -14.53% 1,739.07% -97.66% 58.87% 21.21% 110.72%
EBITDA Q/Q Growth		 -21.18% 56.38% -135.71% 10.32% -14.36% 225.24% -185.82% 5.47% -3.21% 16.64%
EBIT Q/Q Growth		 -17.07% 48.11% -136.70% 10.99% -14.84% 221.43% -183.66% 4.81% -3.42% 6.91%
NOPAT Q/Q Growth		 -11.39% 2.54% -11.17% -3.25% -5.99% 275.30% -154.86% -0.73% -1.53% 6.07%
Net Income Q/Q Growth		 -52.29% 65.00% -151.53% 14.19% -16.08% 248.61% -169.10% 7.72% -6.17% 6.53%
EPS Q/Q Growth		 -52.94% 65.38% -146.30% 18.80% -12.96% 256.56% -163.35% 8.26% -5.41% 6.84%
Operating Cash Flow Q/Q Growth		 -42.51% 7.12% -58.71% 22.90% -6.04% 250.44% -173.85% 16.78% -6.16% 13.34%
Free Cash Flow Firm Q/Q Growth		 -0.18% -32.34% -214.89% -6.84% -24.57% 98.52% -5,730.83% 4.78% 2.27% 8.63%
Invested Capital Q/Q Growth		 -3.86% 9.32% 13.55% 12.28% 9.51% 11.83% 13.18% 14.91% 12.74% 12.83%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -546.81% -188.09% -449.05% -484.62% -648.42% 44.16% -1,506.92% -896.64% -763.49% -302.03%
Operating Margin		 -577.90% -444.10% -408.66% -507.79% -629.72% 42.02% -1,405.29% -891.06% -746.40% -332.71%
EBIT Margin		 -548.43% -224.38% -439.61% -470.91% -632.73% 41.78% -1,491.47% -893.66% -762.46% -336.85%
Profit (Net Income) Margin		 -693.56% -191.39% -398.46% -411.49% -558.88% 45.16% -1,331.57% -773.45% -677.47% -300.51%
Tax Burden Percent		 134.18% 102.68% 0.00% 100.00% 100.00% 299.35% 0.00% 100.04% 100.00% 47.80%
Interest Burden Percent		 94.25% 83.07% 0.00% 87.38% 88.33% 36.11% 0.00% 86.51% 88.85% 186.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -40.23% -37.06% -39.78% -40.60% -42.01% -15.46% -16.09% -17.17% -18.29% -43.94%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -40.23% -9.71% -24.21% -27.23% -39.08% 11.27% -399.90% -240.96% -216.57% -16.69%
Return on Assets (ROA)		 -50.88% -8.28% -21.94% -23.80% -34.52% 12.18% -357.02% -208.55% -192.43% -14.89%
Return on Common Equity (ROCE)		 -40.23% -37.06% -39.78% -40.60% -42.01% -15.46% -16.09% -17.17% -18.29% -43.94%
Return on Equity Simple (ROE_SIMPLE)		 -44.15% 0.00% -41.54% -40.31% -40.27% 0.00% -14.75% -16.74% -18.15% 0.00%
Net Operating Profit after Tax (NOPAT)		 -64 -62 -69 -72 -76 133 -73 -73 -75 -70
NOPAT Margin		 -404.53% -310.87% -286.06% -355.46% -440.80% 42.02% -983.70% -623.74% -522.48% -232.90%
Net Nonoperating Expense Percent (NNEP)		 -4.45% 2.34% -2.38% -1.01% -1.92% 0.88% -2.39% -1.69% -2.28% -1.99%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.49% - - - 13.54% - - - -9.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 138.08% 113.20% 97.03% 122.57% 147.79% 13.68% 360.65% 251.67% 185.82% 95.32%
R&D to Revenue		 539.83% 430.91% 411.62% 485.23% 581.92% 44.30% 1,144.64% 739.39% 660.58% 337.39%
Operating Expenses to Revenue		 677.90% 544.10% 508.66% 607.79% 729.72% 57.98% 1,505.29% 991.06% 846.40% 432.71%
Earnings before Interest and Taxes (EBIT)		 -87 -45 -106 -95 -109 132 -111 -105 -109 -101
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -86 -38 -109 -97 -111 140 -112 -106 -109 -91
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.69 3.76 2.91 3.00 2.45 2.26 2.95 2.26 2.55 2.80
Price to Tangible Book Value (P/TBV)		 4.69 3.76 2.91 3.00 2.45 2.26 2.95 2.26 2.55 2.80
Price to Revenue (P/Rev)		 36.45 45.24 28.90 30.36 23.36 5.87 7.46 5.47 5.78 32.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 24.55 27.54 15.09 16.97 10.90 2.72 4.43 2.61 3.13 18.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 24.13 74.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 39.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.31 -1.31 -1.43 -1.39 -1.41 -1.32 -1.29 -1.25 -1.24 -1.19
Leverage Ratio		 1.60 1.81 1.75 1.72 1.77 1.63 1.61 1.57 1.57 1.49
Compound Leverage Factor		 1.51 1.50 0.00 1.50 1.56 0.59 0.00 1.36 1.39 2.79
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.74 2.33 1.69 2.03 1.33 3.03 3.12 2.13 2.21 1.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.64 4.89 4.92 5.22 4.72 5.89 5.99 5.81 5.69 4.82
Quick Ratio		 4.58 4.82 4.82 5.12 4.61 5.79 5.85 5.69 5.57 4.67
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 212 143 -165 -176 -219 -3.26 -190 -181 -177 -161
Operating Cash Flow to CapEx		 -632.02% -837.56% -1,825.08% -523.36% -1,129.64% 3,763.53% -4,091.35% -4,232.99% -5,588.14% -2,571.21%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.07 0.04 0.06 0.06 0.06 0.27 0.27 0.27 0.28 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.01 0.61 0.71 0.68 0.68 3.14 2.97 2.87 2.90 0.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -380 -345 -298 -261 -237 -209 -181 -154 -134 -117
Invested Capital Turnover		 -0.38 -0.25 -0.22 -0.26 -0.26 -1.37 -1.51 -1.70 -1.89 -0.39
Increase / (Decrease) in Invested Capital		 -276 -206 96 105 144 136 117 107 102 91
Enterprise Value (EV)		 2,257 1,678 1,157 1,361 889 1,029 1,598 920 1,093 1,203
Market Capitalization		 3,352 2,756 2,217 2,434 1,905 2,219 2,693 1,929 2,019 2,054
Book Value per Share		 $10.16 $10.41 $10.52 $10.65 $9.84 $12.04 $11.18 $10.38 $9.60 $8.86
Tangible Book Value per Share		 $10.16 $10.41 $10.52 $10.65 $9.84 $12.04 $11.18 $10.38 $9.60 $8.86
Total Capital		 714 733 762 812 779 981 913 854 791 734
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,095 -1,078 -1,059 -1,073 -1,015 -1,190 -1,095 -1,008 -926 -851
Capital Expenditures (CapEx)		 12 8.26 6.02 16 7.95 3.59 2.44 1.96 1.58 2.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -225 -209 -196 -188 -196 -184 -160 -156 -146 -155
Debt-free Net Working Capital (DFNWC)		 870 869 863 885 819 1,005 934 852 779 696
Net Working Capital (NWC)		 870 869 863 885 819 1,005 934 852 779 696
Net Nonoperating Expense (NNE)		 46 -24 27 11 20 -9.94 26 18 22 20
Net Nonoperating Obligations (NNO)		 -1,095 -1,078 -1,059 -1,073 -1,015 -1,190 -1,095 -1,008 -926 -851
Total Depreciation and Amortization (D&A)		 0.26 7.27 -2.29 -2.76 -2.70 7.53 -1.15 -0.35 -0.15 10
Debt-free, Cash-free Net Working Capital to Revenue		 -244.15% -342.80% -256.03% -234.22% -240.68% -48.82% -44.35% -44.26% -41.89% -243.49%
Debt-free Net Working Capital to Revenue		 946.20% 1,426.96% 1,125.36% 1,104.38% 1,004.46% 266.20% 258.93% 241.69% 222.88% 1,095.88%
Net Working Capital to Revenue		 946.20% 1,426.96% 1,125.36% 1,104.38% 1,004.46% 266.20% 258.93% 241.69% 222.88% 1,095.88%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.56) ($0.54) ($1.33) ($1.08) ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09)
Adjusted Weighted Average Basic Shares Outstanding		 70.34M 70.02M 72.27M 76.34M 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M
Adjusted Diluted Earnings per Share		 ($1.56) ($0.54) ($1.33) ($1.08) ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09)
Adjusted Weighted Average Diluted Shares Outstanding		 70.34M 70.02M 72.27M 76.34M 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 70.47M 72.40M 76.22M 79.20M 81.50M 81.66M 82.31M 82.42M 82.81M 83.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -64 -62 -69 -72 -76 93 -73 -73 -75 -70
Normalized NOPAT Margin		 -404.53% -310.87% -286.06% -355.46% -440.80% 29.41% -983.70% -623.74% -522.48% -232.90%
Pre Tax Income Margin		 -516.90% -186.40% 0.00% -411.49% -558.88% 15.09% 0.00% -773.12% -677.47% -628.67%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.08% -0.07% -0.08% -0.10% -0.22% -0.48% -0.42% -0.27% 0.00% 0.00%

Frequently Asked Questions About Beam Therapeutics' Financials

When does Beam Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Beam Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Beam Therapeutics' net income changed over the last 5 years?

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$376.74 million in 2024, rising from -$78.33 million in 2019. The previous period was -$132.53 million in 2023.

What is Beam Therapeutics's operating income?
Beam Therapeutics's total operating income in 2024 was -$415.57 million, based on the following breakdown:
  • Total Gross Profit: $63.52 million
  • Total Operating Expenses: $479.09 million
How has Beam Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $63.52 million in 2024, a change of 352,777.8%.

How much debt does Beam Therapeutics have?

Beam Therapeutics' total liabilities were at $370.28 million at the end of 2024, a 22.6% decrease from 2023, and a 571.4% increase since 2019.

How much cash does Beam Therapeutics have?

In the past 5 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $281.97 million as of their latest financial filing in 2024.

How has Beam Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 8.86 in 2024, a change of -128.5%.


Related Companies

This page (NASDAQ:BEAM) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
China’s next move could destroy U.S. tech
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...
Investors Alley | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...
Golden Portfolio | Sponsored